Image For Activity Cover
Thyroid Strategies for Endocrinologists
Release: 7/21/2022 | Expiration: 7/21/2023
Info and Disclaimers

Learning Objectives

Upon completion of the activity, participants should be able to:

  • Analyze recent trends regarding hypothyroid management in the United State, use of statins in conjunction with IV glucocorticoids in the treatment of Graves eye disease and recent data informing management for the thyroid cancer risk spectrum
  • Interpret serum T3 and serum T4 levels on LT4-treated patients and current approaches to LT3 and use in treatment of hypothyroidism
  • Review strengths and weaknesses of using different classes of Thyroglobulin (Tg) method to monitor Differentiated Thyroid Cancer (DTC) patients amd Diagnose and manage checkpoint inhibitors-induced thyroid dysfunction
  • Describe how the latest therapeutic considerations are shaping the new treatment paradigm of hyperthyroidism during pregnancy
  • Describe FDA approved and  investigational targeted therapies for thyroid cancer in the context of clinical trials

Accreditation

Target Audience

This educational initiative is intended for Endocrinologists.

Accreditation Statement

The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

 

First

MI

Last

Credentials

Position

Institution

Role

Disclosure(s)

Benjamin

J.

Gigliotti

MD

Assistant Professor of Medicine

University of Rochester

Speaker

Blueprint Medicines (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- RET+ Virtual Thyroid Discussion Forum (a 7-hour advisory board commitment), started 3/3/21, ended 3/17/21)

Alex

 

Tessnow

MD

Associate Professor

University of Texas Southwestern Medical Center

Speaker/Moderator

Horizon (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Spectrix Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Antonio

C.

Bianco

MD, PhD

Professor of Medicine

University of Chicago

Speaker

Abbott/AbbVie (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Allergan (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Synthonic (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Giuseppe

 

Barbesino

MD

Assistant Professor 

Massachusetts General Hospital/Harvard Medical School

Speaker

Horizon Pharma (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Anupam

 

Kotwal

MD

Assistant Professor 

University of Nebraska Medical Center

Speaker

Horizon Therapeutics, Inc. (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Maria

E.

Cabanillas

MD, FACE

Professor 

The University of Texas MD Anderson Cancer Center

Speaker

Bayer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eisai (Self) : Research Grant (Status: Terminated --- 11/15/2019); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Exelixis (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Genentech (Self) : Research Grant (Status: Ongoing); LOXO (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Merck (Self) : Research Grant (Status: Ongoing)

Mimi

 

Hu

MD

Professor 

The University of Texas MD Anderson Cancer Center

Moderator

Eli Lilly (Self) : Contracted Research (Status: Ongoing)

 

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.

Summary
Availability: On-Demand
Expires on Jul 21, 2023
Cost: Member: $127.50
Non-Member: $212.50
Credit Offered:
5.75 CME Credits
5.75 ABIM-MOC Points
Powered By